Effect of retinoic acid on cell proliferation kinetics and retinoic acid receptor expression of colorectal mucosa

Hong-Bo Wei, Xiao-Yan Han, Wei Fan, Gui-Hua Chen, J i-Fu Wang

AIM: To investigate the effect of retinoic acid (RA) on cell proliferation kinetics and retinoic acid receptor (RAR) expression of colorectal mucosa.

METHODS: One hundred sixty healthy male Wistar rats were randomly divided into 4 groups. Rats in groups I and II were subcutaneously injected with dimethylhydrazine (DMH) (20 mg/kg, once a week,) for 7 to 13 weeks, while groups III and IV were injected with normal saline. Rats in groups II and III were also treated with RA (50 mg/kg, every day, orally) from 7th to 15th week, thus group IV was used as a control. The rats were killed in different batches. The expressions of proliferating cell nuclear antigen (PCNA), nucleolar organizer region-associated protein (AgNOR) and RAR were detected.

RESULTS: The incidence of colorectal carcinoma was different between groups I (100 %) and II (15 %) (P<0.01). The PCNA indices and mean AgNOR count in group II were significantly lower than those in group I (F=5.418 and 4.243, P<0.01). The PCNA indices and mean AgNOR count in groups I and II were significantly higher than those in the groups III and IV (in which carcinogen was not used) (F=5.927 and 4.348, P<0.01). There was a tendency in group I that the longer the induction with DMH the higher PCNA index and AgNOR count expressed (F=7.634 and 6.826, P<0.05). However, there was no such tendency in groups III and IV (F=1.662 and 1.984, P=0.05). The levels of RAR in normal and cancerous tissues in groups treated with RA were significantly higher than those in groups not treated with RA (F=6.343 and 6.024, P<0.05).

CONCLUSION: RA decreases the incidence of colorectal carcinoma induced by DMH. Colorectal cancer tissue is associated with abnormal expression of PCNA, AgNOR and RAR. RA inhibits the expression of PCNA and AgNOR, and increases RAR concentration in colorectal tissues.

INTRODUCTION

The occurrence and development of colorectal carcinoma usually need a long and multistep process. Intervention treatment to block the canceration course from precancerous lesion of colorectal carcinoma is an important step to decrease the incidence of colorectal carcinoma. Some results obtained from in vitro experiments have shown that retinoic acid (RA) plays a role in blocking canceration induced by carcinogen and promotes normal differentiation of leucocytoma cells[1-3]. However, the effect of RA on colorectal carcinoma, especially on cell proliferation kinetics and the expression of retinoic acid receptor (RAR) of colorectal mucosa, has not been reported. To provide theoretic data on prevention and treatment of colorectal carcinoma, we investigated the effect of RA on cell proliferation kinetics and expression of RAR of colorectal mucosa.

MATERIALS AND METHODS

Animals and groups

One hundred sixty healthy male Wistar rats (body weight 134±12 g) were randomly divided into 4 groups. There were 40 rats in each group. Rats in group I and II were subcutaneously injected with dimethylhydrazine (DMH) (20 mg/kg, once a week,) for 7 to 13 weeks, while groups III and IV were injected with normal saline. Rats in groups II and III were treated with RA (50 mg/kg, every day, orally) from 7th to 15th week, group IV was used as a control. Eight rats in each group were killed randomly at 7th, 14th and 21st week in each group. The other rats were killed at 28th week. The number of colorectal carcinoma lesions was examined, and the normal colorectal tissues were also collected. The colorectal samples were fixed with 10 % formalin and embedded in paraffin. The expression of proliferating cell nuclear antigen (PCNA) and nucleolar organizer region-associated protein (AgNOR) was studied.

Detection of PCNA and AgNOR

Normal colorectal tissues (n=8) and the colorectal tissues (n=8) free of cancer induced by DMH after 7, 14, 21 and 28 weeks, were included. The samples including well-differentiated adenocarcinoma (n=8) and poorly differentiated adenocarcinoma (n=8) were also collected. The immunohistochemical staining method was used to detect PCNA indices[4-7]. Representative regions with a double blind method were selected, and at least 1 000 cells were counted. The rates of positive cells over total cells counted were defined as the PCNA indices. Ptolon one-step method was used for the detection of AgNOR count[8-11].

Detection of retinoic acid receptor (RAR)

Specimen disposal The mesentery tissues were removed and
part of the colorectal tissues was cut to pieces and placed in
DMEM buffer. A tissue was homogenated by a high speed disperser, 4 000 r.min⁻¹ for 10 min and a homogenizer 4 000 r.min⁻¹ for 30 min and then by centrifugation 1 000 r. min⁻¹ for 30 min. The buffer was added to the deposit, and the suspension was centrifugated, 750. r. min⁻¹ for 15 min. Finally, the deposit was made to nucleus fluid. DNA concentration was determined by the dimethylamline method. The rest part of tissues was treated with liquid nitrogen and preserved in an ultra cold storage freezer.

**Receptor radio-ligand binding test**[16-20] All the procedures of the test were carried out at 4 °C. 0.1 ml of nucleus fluid and 0.05 ml of 3H-atRA (2×10⁻¹⁰ mol/L) and 0.05 ml of buffer were mixed at different concentrations (the end concentration was 0.1-10 nM, with 6 concentration points). At the same time, the control test tube of non-specific binding was 200-time of unlabelled 9-cis-atRA. After 20 h, the reaction mixture was filtered with a multi-head collecting device and the free RA was removed, and examined by the filter membrane method. Saturation binding curve, Scatchard diagram and receptor maximum dissociation constant KD were analyzed by a receptor radio-ligand binding analyzing software.

**Statistical analysis**
Experimental results were analyzed by variance analysis and chi-square test with SPSS software. Statistical significance was determined at P<0.05.

**RESULTS**

**Incidence of colorectal carcinoma**
At the 14th week after induction, 12.5 % of rats in group I developed colorectal carcinoma, but colorectal carcinoma was not found in group II. At the 21st and 28th weeks, the incidence of colorectal carcinoma reached 60 % and 100 % respectively in group I, compared with 12 % and 20 % respectively in group II. There were significant differences between the two groups (P<0.05 and P<0.01). All the carcinomas were adenocarcinomas. In group I, 12 cases of adenocarcinoma were well-differentiated and 9 cases were poorly-differentiated. All the 4 cases in group II were well-differentiated (Table 1).

**Table 1** Incidence (%) of colorectal carcinoma in the groups

| Weeks | n | I | II | III | IV |
|-------|---|---|---|---|---|
| 7     | 8 | 0 | 0 | 0 | 0 |
| 14    | 8 | 0 (12.5) | 0 | 0 | 0 |
| 21    | 8 | 5 (60.5) | 1 (12.5) | 0 | 0 |
| 28    | 15 | 15 (100.0) | 3 (20.0) | 0 | 0 |

**Expression of PCNA indices**
At the 7th week, PCNA indices reached 96.75±6.88 and 95.50±4.01, respectively, in group I and group II, which were significantly higher than those in group III and group IV (34.38±6.30 and 33.63±4.75, respectively, P<0.01). In metaphase and late-phase, PCNA indices in group I and group II were continuously increased, especially in group I. PCNA indices in group I reached 168.13±4.34 at the 28th week and approached the level of well-differentiated adenocarcinoma (169.13±11.68), but were still significantly lower than that of poorly-differentiated adenocarcinoma (181.63±23.38, P<0.05). Analysis of variance showed that there was a tendency in group I that the longer the time of induction with DMH prolonged, the AgNOR count already approached the level of well-differentiated adenocarcinoma, but was still significantly lower than that of poorly-differentiated adenocarcinoma (P<0.05).

In comparison between the groups, the results showed that PCNA indices in group I and group II were significantly higher than those in groups III and IV at all stages of carcinoma induction (F=5.927, P<0.01). Moreover, PCNA index in group I was significantly higher than that in groups II at all stages (F=5.418, P<0.01), except at the 7th week (Table 2).

**Table 2 Expression of PCNA indices in groups**

| Weeks | n | I | II | III | IV |
|-------|---|---|---|---|---|
| 7     | 8 | 96.75±6.88 | 95.50±4.01 | 34.38±4.30 | 33.63±6.75 |
| 14    | 8 | 110.88±5.51 | 97.88±9.90 | 35.13±4.91 | 35.88±2.17 |
| 21    | 8 | 149.50±15.15 | 98.25±25.09 | 35.00±5.46 | 34.13±1.39 |
| 28    | 8 | 168.13±4.34 | 98.88±25.30 | 35.88±2.99 | 33.13±3.12 |

**Expression of AgNOR count**
At the 7th week, AgNOR count reached 3.78±0.88 and 3.71±0.95, respectively, in group I and group II, which was significantly higher than that in group III and group IV (P<0.05). As the time of induction with DMH prolonged, the AgNOR count in group I was continuously increased. Analysis of variance showed that there was a tendency in group I that the longer the induction with DMH the higher the AgNOR count (F=6.826, P<0.05). However, there was no such tendency in groups II, III and IV (F=1.984, P>0.05). At the 28th week, the AgNOR count already approached the level of well-differentiated adenocarcinoma, but was still significantly lower than that of poorly-differentiated adenocarcinoma (P<0.05). In comparison between the groups, the results showed that the AgNOR counts in group I and group II were significantly higher than those in groups III and IV at all stages of carcinoma induction (F=4.348, P<0.05). The AgNOR count was significantly higher in group I than that in group II at all stages (F=4.243, P<0.05), except at the 7th week (Table 3).

**Table 3 Expression of AgNOR count in groups**

| Weeks | n | AgNOR count (x 10⁻⁶) |
|-------|---|---------------------|
|       | I | II | III | IV |
| 7     | 8 | 3.78±0.88 | 3.71±0.95 | 2.17±0.53 | 2.45±0.06 |
| 14    | 8 | 5.15±1.87 | 4.30±0.84 | 2.20±0.86 | 2.16±0.80 |
| 21    | 8 | 7.54±0.73 | 4.39±0.62 | 2.20±0.77 | 2.49±0.90 |
| 28    | 8 | 9.37±0.71 | 4.75±0.98 | 2.35±0.01 | 2.38±0.04 |

**Table 3 Expression of AgNOR count in groups**

| Weeks | n | Bmax | KD |
|-------|---|------|----|
|       | I |     |    |
| 7     | 6 | 1.16±0.34 | 1.99±0.25 |
| 14    | 6 | 1.87±0.36 | 2.16±0.18 |
| 21    | 6 | 2.61±0.55 | 2.39±0.43 |
| 28    | 6 | 2.64±0.22 | 2.45±0.23 |

**Expression of RAR**
Six samples of colorectal and cancer tissues were collected randomly from groups I, II, III and IV respectively. Expressions...
of RAR were detected, Bmax and KD were calculated. The Bmax and KD in group I approached the level of cancer tissues (1.0240.21 and 1.74±0.16, P>0.05). The Bmax and KD in group II were significantly higher than those in group I, but significantly lower than those in groups III and IV, (F=6.343 and 6.024, P<0.05).

**DISCUSSION**

Recently, the mechanism of preventing carcinoma by RA has been studied by scholars all over the world. Some researchers reported that leukaemia cells could respond to the effect of differentiation induced by RA to put up the potential of diphasic differentiation\[24-30\]. Some reported that RA could result in reversion of liver cancer cells\[34-35\]. In our research, we found that the incidence of carcinoma developed in RA treatment group (group II) was significantly lower than that in group I during induction. The results showed that retinoic acid (RA) had an effect on blocking canceration induced by carcinogen and decreased the incidence of colorectal cancer.

PCNA is the 36 KD polypeptide which is synthesized and expressed just in proliferating cells. It has been proved that PCNA expression is related to cell generation cycle\[11\]. Expression of PCNA increases in G2 phase gradually, reaches pinnacle in S phase, and decreases in G2/M phase. It plays an important role in understanding cell generation state to detect PCNA indices. The higher the PCNA expression, the higher the malignancy of cell\[12\]. Our experimental results showed that there was a tendency in group I that the longer the interval induced by DMH, the higher the PCNA index would be (P<0.05). At the 28th week, the PCNA indices already approached the level of well-differentiated adenocarcinoma, but were still significantly lower than that of poorly-differentiated adenocarcinoma (P<0.05). The PCNA indices in group II were higher than those in groups III and IV, but still lower than those in group I. RA may have an effect on blocking canceration induced by carcinogen and decreasing the incidence of colorectal carcinoma. The mechanism is not clear, maybe it is related to blocking the transition of cancer cells from G2/M phase to S1/G1 phase. Our results also showed that RA could not block canceration entirely.

AgNOR is the biochemical symbol of rDNA and transcription. AgNOR count can reflect the cell active state and cell malignant trend of carcinoma\[9,10]. We found that AgNOR count of colorectal mucosa cells in group II was significantly lower than that in group I, but significantly higher than that in groups III and IV during the period of induction. The reasonable explanation was that RA could inhibit the process of canceration induced by carcinogen but could not block canceration entirely.

Our results showed that there were plenty of RARs in colorectal tissues. The normal RAR contents in colorectal cells were 2.64±1.8 f mol/µg DNA, and KD was 2.45±1.8 nmol. However, RAR contents in colorectal cancer cells decreased significantly (1.02±0.2 f mol/µg DNA, and 1.74±0.16 nmol). It is possible that the development of colorectal carcinoma is related to abnormal expression of RAR, and especially decrease of RAR content. After interference treatment with RA, the expression of RAR increased. The carcinogenic course induced by DMH was slowed down distinctly. The results revealed that RA had an effect on inhibiting cellular proliferation and RA could regulate the expression of RAR\[22,30\].

There are plenty of similarities between human colorectal cancer and experimental colorectal cancer. However, it is possible that colorectal cancer occurs in total colorectal mucosa under the action of carcinogenic factor. It is possible that clinical application of RA can inhibit the precancerous lesion of colorectal carcinoma, block the canceration course, and decrease the incidence of colorectal cancer\[11,33\]. It is expected that clinical application of RA after colorectal operation would prevent and decrease the recurrence of carcinoma.

**REFERENCES**

1. Adachi Y, Itoh F, Yamamoto H, Iku S, Matsuno K, Arimura Y, Imai K. Retinoic acids reduce matrilysin (matrix metalloproteinase 7) and inhibit tumor cell invasion in human colon cancer. Tumour Biol 2003; 22: 247-253
2. Szabo W, Jiang W, Tice DA, Rubinfeld B, Hollingshead PG, Fong SE, Duggar DL, Pham T, Yansura DG, Wong TA, Grimaldi JC, Corpuz RT, Singh JS, Frantz GD, Devaux B, Crowley CW, Schwall RH, Eberhard DA, Rastelli L, Polakis P, Pennica D. Overexpression of the retinoic acid-responsive gene Sfral in human cancers and its synergistic induction by Wnt-3 and retinoic acid. Cancer Res 2001; 61: 4197-4205
3. Paulsen JE, Lutzow-Holm C. In vivo growth inhibition of human colon carcinoma cells (HT-29) by all-trans-retinoic acid, difluoromethylornithine, and colon mitosis inhibitor, individually and in combination. Anticancer Res 2003; 23: 3485-3489
4. Wu W, Zhang X, Yan X, Wang J, Zhang J, Li Y. Expressions of beta-catenin, p53 and proliferating cell nuclear antigen in the carcinogenesis of colorectal adenoma. Zhonghua Zhenjiu Zazhi 2002; 24: 264-267
5. Boonsong A, Curran S, McKay CA, Cassidy J, Murray GL, McLeod HL. Topoisomerase I protein expression in primary colorectal cancer and lymph node metastases. Hum Pathol 2002; 33: 1134-1139
6. Izawa H, Yamamoto H, Ikeda M, Ikeda K, Fukunaga H, Yasui M, Ikenaga M, Sekimoto M, Monden T, Matsuura N, Monden M. Analysis of cyclin D1 and CDK expression in colorectal polyps containing neoplastic foci: a study of proteins extracted from paraffin sections. Oncol Rep 2002; 9: 1313-1318
7. Kohno H, Tanaka T, Kawabata K, Hirose Y, Sugie S, Tsuda H, Mori H, Silymarin, a naturally occurring polyphenolic antioxidant flavonoid, inhibits azoxymethane-induced colon carcinogenesis in male F344 rats. Int J Cancer 2001; 101: 463-468
8. Barnett KT, Fokum FD, Malafa MP. Vitamin E succinate inhibits colon cancer liver metastases. J Surg Res 2002; 106: 292-298
9. Lavezzi AM, Ottaviani G, De Ruberto F, Fichera G, Matturri L. Prognostic significance of different biomarkers (DNA content, PCNA, karyotype) in colorectal adenomas. Anticancer Res 2002; 22: 2077-2083
10. McKay JA, Douglas JJ, Ross VG, Curran S, Loane JF, Ahmed FY, Cassidy J, McLeod HL, Murray GL. Analysis of key cell-cycle checkpoint proteins in colorectal tumours. J Pathol 2002; 196: 386-393
11. Ohishi T, Kishimoto Y, Miura N, Shiota G, Kohri T, Hara Y, Hasegawa J, Isemura M. Synergistic effects of (-)-epigallocatechin gallate with sulindac against colon carcinogenesis of rats treated with azoxymethane. Cancer Lett 2002; 177: 49-56
12. Yamada Y, Yoshimi N, Hirose Y, Matsuura K, Katayama M, Sakata K, Shimizu M, Kuno T, Mori H. Sequential analysis of morphological and biological properties of beta-catenin-accumulated crypts, provable premalignant lesions independent of aberrant crypt foci in rat colon carcinogenesis. Cancer Res 2001; 61: 1874-1876
13. Hung LC, Pong VF, Cheng CR, Wong FI, Chu RM. An improved system for quantifying AgNOR and PCNA in canine tumors. Anticancer Res 2002; 20: 3273-3280
14. Derenzini M, Trere D, Pession A, Govoni M, Sirri V, Chicco P. Nucleolar size indicates the rapidity of cell proliferation in cancer tissues. J Pathol 2000; 191: 181-186
15. Eminovic-Behrem S, Trobonjaca Z, Petrovecki M, Dobi-Babic R, Dujmovic M, Jonic N. Prognostic significance of DNA ploidy pattern and nucleolar organizer regions (AgNOR) in colorectal carcinoma. Croat Med J 2000; 41: 154-158
16. Ofner D. In situ standardised AgNOR analysis: a simplified method for routine use to determine prognosis and chemotherapy efficiency in colorectal adenocarcinoma. Micron 2000; 31: 161-164
17. Suga T, Nakamura S, Habano W, Uesugi N, Sato H, Yoshida T, Orii S. Usefulness of proliferative activity, DNA ploidy pattern and p53 products as diagnostic adjuncts in colorectal adenomas and intramucosal carcinomas. Pathol Int 1999; 49: 617-625
Nanashima A, Yamaguchi H, Shibasaki S, Sawai T, Yasutake T, Tsuji T, Nakagoe T, Ayabe H. Proliferation of hepatic metastases of colorectal carcinoma: relationship to primary tumours and prognosis after hepatic resection. J Gastroenterol Hepatol 1999; 14: 61-66

Guan RJ, Ford HL, Fu Y, Li Y, Shaw LM, Pardee AB. Drg-1 as a differentiation-related, putative metastatic suppressor gene in human colon cancer. Cancer Res 2000; 60: 749-755

Lee MO, Han SY, Jiang S, Park JH, Kim SJ. Differential effects of retinoic acid on growth and apoptosis in human colon cancer cell lines associated with the induction of retinoic acid receptor beta. Biochem Pharmacol 2000; 59: 485-496

Sarraf P, Mueller E, Smith WM, Wright HM, Kum JB, Aaltonen LA, de la Chapelle A, Spiegelman BM, Eng C. Loss-of-function mutations in PPAR gamma associated with human colon cancer. Mol Cell 1999; 3: 799-804

Nicke B, Riecken EO, Rosewicz S. Induction of retinoic acid receptor beta mediates growth inhibition in retinoid resistant human colon carcinoma cells. Gut 1999; 45: 51-57

Zheng Y, Kramer PM, Lubet RA, Steele VE, Kellogg GJ, Pereira MA. Effect of retinoids on AOM-induced colon cancer in rats: modulation of cell proliferation, apoptosis and aberrant crypt foci. Carcinogenesis 1999; 20: 255-260

Teraishi F, Kadowaki Y, Tango Y, Kawashima T, Urnlaka T, Kagawa S, Tanaka N, Fujiwara T. Ectopic p21sdi1 gene transfer induces retinoic acid receptor beta expression and sensitizes human cancer cells to retinoid treatment. Int J Cancer 2003; 103: 833-839

Narayanan BA, Narayanan NK, Simi B, Reddy BS. Modulation of inducible nitric oxide synthase and related proinflammatory genes by the omega-3 fatty acid docosahexaenoic acid in human colon cancer cells. Cancer Res 2003; 63: 972-979

Wei HB, Wang JF, Chen GH. Effect of retinoic acid (RA) on the T-lymphocyte subsets and T-cell colony of patients with colorectal cancer. Ai Zhong 2003; 22: 202-205

Lee MO, Kang HJ. Role of coactivators and corepressors in the induction of the RARbeta gene in human colon cancer cells. Biol Pharm Bull 2002; 25: 1298-1302

Tao L, Kramer PM, Wang W, Yang S, Lubet RA, Steele VE, Pereira MA. Altered expression of c-myc, p16 and p27 in rat colon tumors and its reversal by short-term treatment with chemopreventive agents. Carcinogenesis 2002; 23: 1447-1454

Ahmed KM, Shitara Y, Takenoshita S, Kuwano H, Shinozawa T. Association of an intronic polymorphism in the midkine (MK) gene with human sporadic colorectal cancer. Cancer Lett 2002; 180: 159-163

Li Y, Zhang H, Xie M, Hu M, Ge S, Yang D, Wan Y, Yan B. Abundant expression of Dec1/stra13/sharp2 in colon carcinoma: its antagonizing role in serum deprivation-induced apoptosis and selective inhibition of procaspase activation. Biochem J 2002; 367 (P2): 413-422

Ye J, Lu H, Zhou J, Wu H, Wang C. Inhibitory effect of all-trans-retinoid and polyphenal-100 on microsatellite instability in a colon cancer line. Zhonghua Yi Xue Za Zhi 2002; 19: 190-193

Wong NA, Pignatelli M. Beta-catenin: a linchpin in colorectal carcinogenesis? Am J Pathol 2002; 160: 369-401

Lamprecht SA, Lipkin M. Cellular mechanisms of calcium and vitamin D in the inhibition of colorectal carcinogenesis. Ann N Y Acad Sci 2001; 952: 73-87

Paulsen JE, Elgio K. Effect of tumour size on the in vivo growth inhibition of human colon carcinoma cells (HT-29) by colon mitosis inhibitor. In Vivo 2001; 15: 397-401

Pafiesak A, Menzl I, Feuchter A, Bode JC, Bode C. Inhibition of retinol oxidation by ethanol in the rat liver and colon. Gut 2000; 47: 825-831

Edited by Xia HHX and Wang XL